menu search

Medivir to report new and updated data from ongoing phase 2a hcc study as part of its q3 report on friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a ph...

October 25, 2023, 2:46 am

Rayzebio: initiating coverage with buy rating and a price target of $43

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re...

October 10, 2023, 2:10 pm

Hepion pharmaceuticals to participate in 2023 cantor global healthcare conference

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Art...

September 21, 2023, 4:05 pm

Hepion pharmaceuticals schedules conference call to review topline results from phase 2 ‘altitude-nash' liver function trial of rencofilstat

EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artif...

May 19, 2023, 4:05 pm

Tempest to report early results from global randomized phase 1b/2 combination study of tpst-1120 in first-line hepatocellular carcinoma

Webcast Conference Call Friday, April 28, 2023, at 8:30 a.m. ET BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasd...

April 27, 2023, 8:58 pm

Tempest to report early results from global randomized phase 1b/2 combination study of tpst-1120 in first-line hepatocellular carcinoma

BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-...

April 27, 2023, 4:58 pm

Aligos therapeutics to present data from chronic hepatitis b and hepatocellular carcinoma programs at the european association for the study of the liver (easl) congress 2023

SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company f...

April 11, 2023, 6:50 pm

Omega therapeutics to present trial-in-progress poster for phase 1/2 mychelangelo™ i study at the american society of clinical oncology gastrointestinal cancers symposium

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pion...

January 17, 2023, 7:00 am

Q biomed says new publication shows superior safety and efficacy of uttroside-b versus fda approved drug sorafenib

Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior s...

July 26, 2022, 10:10 am

Astrazeneca's tremelimumab/imfinzi combo regime goes under priority fda review for liver cancer

The FDA has accepted for review AstraZeneca Plc's (NASDAQ: AZN) marketing application for tremelimumab as a single priming dose added to Imfinzi (d...

April 25, 2022, 7:15 am

Omega therapeutics to present preclinical data for otx-2002 at the american association for cancer research annual meeting 2022

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneeri...

March 8, 2022, 5:05 pm

Astrazeneca rolls out "unprecedented' three year survival data for imfinzi/treme combo in liver cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresec...

January 19, 2022, 12:50 pm

Astrazeneca rolls out "unprecedented' three year survival data for imfinzi/treme combo in liver cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresec...

January 19, 2022, 12:50 pm

Astrazeneca rolls out "unprecedented' three year survival data for imfinzi/treme combo in liver cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresec...

January 19, 2022, 12:50 pm


Search within

Pages Search Results: